BDC, NEA to vote for $1.31 bln acquisition of Clementia
BDC Capital's Healthcare Venture Fund and New Enterprises Associates (NEA) have agreed to vote in favour of Ipsen's acquisition of Clementia Pharmaceuticals (Nasdaq: CMTA). Last month, France's Ipsen agreed to acquire Clementia, a Montréal-based developer of treatments for ultra-rare bone disorders and other diseases, for US$1.31 billion ($1.72 billion). BDC and NEA, which respectively own about 14 percent and 7.1 percent of Clementia's issued and outstanding shares, join OrbiMed Advisors and other investors that have already indicated approval of the deal. These shareholders together hold a 51.7 percent interest in the company.
6 March 2019•3 mins read
